MUC1 and cancer: In spite of potential challenges with pharmacokinetic properties, glycopeptide structures linked to immunostimulants have in recent years shown to be highly efficient as potential MUC1 anti-cancer vaccines and a number of candidates are in clinical trials [144,145].